Reading time ( words)
Endomag has renewed a five-year manufacturing contract with ITL Group for on-going production of its commercially successful surgical guidance system, the Sentimag platform.
The Sentimag platform helps surgeons to mark, detect and accurately remove tumours or lymph nodes causing minimal damage to the breast tissue. The technology works like a metal detector, which when placed near the skin’s surface can detect Endomag’s magnetic seed (Magseed®) or magnetic lymph node tracer (Magtrace).
ITL Group successfully supported Endomag as it took the device from a proof of principle instrument to state-of-the-art medical technology. Endomag has won several awards for the design and production of the Sentimag® platform, including the Queen’s Award for Enterprise in Innovation in 2018.
"I am delighted to continue our relationship with the team at ITL. Their expertise in design, tooling and manufacture has helped fulfil our technology’s potential as we strive to make cancer care better for patients everywhere. I am looking forward to continuing to work together, as we grow to meet global demand for the Sentimag® system," said Eric Mayes, Endomag CEO.
ITL manufactures the platform in Britain for use all around the world. To this day, the Sentimag system is the world's most sensitive handheld magnetic probe, used in over 60,000 breast cancer procedures at over 400 hospitals in more than 30 countries.
"From humble beginnings as a spin-out from UCL, to now being one of ITL’s longest-standing customers, it has been an absolute pleasure to work alongside Eric and the team as they’ve grown from strength to strength. We’re delighted to secure another five years manufacturing with Endomag. They are a fantastic company to work alongside and we greatly value the opportunity to work with them longer term as they strive to improve the global standard of cancer care," ITL Managing Director Tom Cole said.